Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.

摘要: Purpose of review This will focus on the emerging role tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL-receptors in pathophysiology hematopoiesis and potential therapeutic applications either recombinant TRAIL or anti-TRAIL-R1/-R2 agonistic antibodies for treatment hematological malignancies. Recent findings While CD34+ stem/progenitor cells do not express TRAIL-receptors are protected from TRAIL-induced apoptosis, accumulating evidence points to a elevated expression/release at bone marrow level aplastic anemia, Fanconi myelodysplastic syndromes. In-vitro data show promising synergistic effects association with proteasome histone deacetylase inhibitors, natural compounds small molecules therapy myeloid lymphoid Moreover, although both well tolerated vivo, advantage avoiding neutralizing activity soluble receptor osteoprotegerin. Summary chronic pathological elevation might contribute impairment normal hematopoiesis, use appears particularly malignancies particular, multiple myeloma, especially if used innovative compounds.